<DOC>
	<DOCNO>NCT02730312</DOCNO>
	<brief_summary>The purpose study determine safety tolerability weekly intravenous ( IV ) administration XmAb14045 determine maximally tolerate dose ( MTD ) first dose , determine MTD second subsequent infusion .</brief_summary>
	<brief_title>PH 1 Study Evaluate Safety Tolerability XmAb14045 Patients With CD123-expressing Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Diagnosis 1 follow disease : Primary secondary AML ( include erythroleukemia eosinophilic leukemia , exclude acute promyelocytic leukemia ) Bcell ALL BPDCN CML blast phase , resistant intolerant tyrosine kinase inhibitor therapy Patients relapse refractory disease available standard therapy ECOG performance status 02 Not candidate , refuse treatment hematopoietic stem cell transplantation Cytotoxic chemotherapy , radiotherapy , immunotherapy investigational agent treatment within 2 week first dose study drug Prior therapy CD123 IL3Rdirected immunotherapy , include monospecific bsAbs , immunoconjugates , chimeric antigen receptormodified Tcell therapy Failure recover Grade 3 4 toxicity previous treatment ( unrelated malignant bone marrow involvement ) Known uncontrolled central nervous system involvement malignant disease White blood cell ( WBC ) count â‰¥10,000/mm3 symptom leukostasis Diagnosis promyelocytic leukemia Aspartate aminotransferase alanine aminotransferase screen &gt; 3.0 x upper limit normal ( ULN ) unless consider due leukemic organ involvement Bilirubin &gt; 1.5 x ULN , unless prior diagnosis documentation leukemic organ involvement , ongoing hemolysis , Gilbert 's syndrome Serum creatinine &gt; 2.0 x ULN , estimate creatinine clearance &lt; 40mL/min History evidence clinically unstable/uncontrollable disorder , condition disease primary malignancy , opinion Investigator would pose risk patient safety interfere study evaluation Evidence active , uncontrolled bacterial , viral , parasitic fungal infection within 1 week first dose study drug Positive test human immunodeficiency virus ( HIV ) I II antibody , hepatitis B surface antigen core antibody , hepatitis C virus antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>B-ALL</keyword>
	<keyword>BPDCN</keyword>
	<keyword>CML</keyword>
	<keyword>Blast Crisis</keyword>
</DOC>